Latest Conference Coverage

The neurologist and movement disorders fellow at University Hospitals Cleveland Medical Center shared his experiences engaging with a diverse community of clinicians at the ATMRD Congress and in clinical practice. [WATCH TIME: 2 minutes]

The director of the Montefiore Headache Center provided commentary on how analyses presented at AHS 2022 further support the benefits intranasal zavagepant bring to the migraine treatment landscape. [WATCH TIME: 5 minutes]

The director of the Montefiore Headache Center provided insight on an open-label study presented at AHS 2022 that highlighted rimegepant’s (Nurtec ODT; Biohaven) impact both as a preventative and acute medication. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke and cerebrovascular disease.

The director of the Montefiore Headache Center discussed the intuitiveness and advantages the Migraine Clinical Outcome Assessment System, or MiCOAS, grant provides to clinical trials and patients with migraine. [WATCH TIME: 5 minutes]

Ruth Benca, MD, PhD, a professor and the chair of Psychiatry & Human Behavior at Wake Forest School of Medicine, provided insight on the age- and sex-related differences in sleep disorders, and the needed research on the effects of therapeutics in older populations.

The pediatric neurologist and headache specialist at the University of Calgary and Alberta Children’s Hospital spoke about the need for improved funding and research efforts for the migraine population. [WATCH TIME: 5 minutes]

Rachel Alvarez and Gustavo Dziewczapolski, PhD, of Cure CMD spoke about the benefits of attending the biennial Scientific & Family Conference to learn more about congenital muscle diseases and interact with the patient community.

Chaired by Stephen Krieger, MD, the presentations also feature Mount Sinai experts Erin Beck, MD, PhD; James Sumowski, PhD; and Ilana Katz Sand, MD. [WATCH TIME: 1 hour, 34 minutes]

The senior vice president for research and training at the Kessler Foundation discussed the assessment of cognitive challenges among patients with multiple sclerosis and planning for treatment options when necessary. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.

Richard Bogan, MD, FCCP, FAASM, associate clinical professor, University of South Carolina School of Medicine, provided commentary on multifunctional capabilities of Xywav and how the medication has improved care for narcolepsy and idiopathic hypersomnia.

The senior vice president for research and training at the Kessler Foundation spoke about the critical need to prioritize cognitive challenges among patients with multiple sclerosis, as it remains among the chief complaints. [WATCH TIME: 4 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Serena L. Orr, MD, MSc. [LISTEN TIME: 32 minutes]

Jean Hubble, MD, semi-retired neurologist and consultant, spoke with the PMD Alliance at the ATMRD Congress about the advances made in the field and her hopes for the future of therapeutics and clinical care.

The assistant professor of neurology and codirector of the Neurology Residency Program at MedStar Georgetown University Hospital and presenter at ATMRD offered his insight into the benefits of multispecialty meetings. [WATCH TIME: 3 minutes]

The chair of Cleveland Clinic’s Department of Physical Medicine provided insight on a newly approved modality aimed to improve rehabilitation efforts for patients with multiple sclerosis. [WATCH TIME: 3 minutes]

The NeurologyLive® team assembled some of the best discussions with leaders in headache and migraine medicine following the 2022 American Headache Society (AHS) Annual Scientific Meeting.

The assistant professor of neurology and codirector of the Neurology Residency Program at MedStar Georgetown University Hospital shared his thoughts on the 2022 ATMRD Congress and the steps forward made in patient awareness of therapeutic options. [WATCH TIME: 3 minutes]

The NeurologyLive® team has compiled a roundup of our discussions with leaders in the multiple sclerosis field following the 2022 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC).

As the individualized needs of patients are further prioritized in Parkinson disease care, the director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute shared her perspective on shared decision-making. [WATCH TIME: 4 minutes]

The head of the MS center at University Hospital Basel provided insight on the role of BTK inhibitors and how the multiple sclerosis community views the potential of neurofilament light as a key biomarker of neurodegeneration. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

The director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute discussed the importance of a multidisciplinary approach to movement disorders and the hot topics of conversation at ATMRD. [WATCH TIME: 2 minutes]

The associate neurologist at Brigham and Women’s Hospital provided insight on the current state of promising targets in progressive MS and why anti-CD3 therapy might be a new consideration for future trials. [WATCH TIME: 2 minutes]

After 26 weeks of treatment, those on fosgonimeton alone without acetylcholinesterase inhibitors showed a potentially beneficial change in event-related potential P300 latency, an outcome of working memory processing speed.

The director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute spoke about her time at the 2022 ATMRD Congress and how successful communication between patients and providers is rooted in accessibility. [WATCH TIME: 2 minutes]

A trio of experts in multiple sclerosis exchanges their thoughts on the use of the sphingosine-1 phosphate modulating class of medicines in treating the disease. [WATCH TIME: 3 minutes]